Ultrahuman launches $800 AI blood test analyzing 120+ health markers

Ultrahuman has launched Blood Vision, an AI-powered blood-testing platform in the US that analyzes over 120 blood markers for $800 annually, requiring users to provide 8-10 vials of blood at medical labs. The service promises to predict future health risks including cancer susceptibility and longevity markers, positioning itself as a comprehensive alternative to traditional blood testing in the growing convergence between wearable technology and healthcare services.

What you should know: Blood Vision represents Ultrahuman’s expansion beyond its smart ring product into predictive health analytics using extensive blood work.

• Users visit medical labs to provide eight to ten vials of blood, which are analyzed for over 120 markers including glucose, cholesterol, proteins, and other health indicators.
• Results are delivered through an AI-powered clinician via the Ultrahuman app, with assessments focused on longevity and lifestyle factors.
• The company offers a mid-year follow-up test measuring over 60 blood markers as part of the annual membership.

The big picture: The launch reflects a broader trend of wearable technology companies partnering with medical facilities to offer comprehensive health monitoring services.

• Oura Ring, another wearable device maker, recently partnered with Essence Healthcare to provide patients with continuous health insights through wearable devices.
• Whoop has teased an Advanced Labs feature for its MG tracker that would similarly combine blood tests with wearable data for clinician analysis.
• These collaborations represent the increasing convergence between traditional healthcare and consumer health technology.

Privacy concerns: The extensive data collection raises questions about health information security at technology startups versus established healthcare providers.

• Ultrahuman’s privacy policy states users can request details of collected health information, request data deletion, and learn about data sharing practices.
• The company promises: “You own your data and control our usage of your data. We will never sell your data to third-parties.”
• ZDNET’s health tech editor Nina Raemont expressed wariness about providing extensive blood samples and health data to a startup, questioning whether tech companies follow the same security protocols as healthcare organizations.

What they’re saying: The author acknowledges both the potential and the risks of this emerging technology.

• “It’s my duty as ZDNET’s wearable health tech editor to try out products that are quite literally at the bleeding edge, but am I risking my privacy by doing so?” Nina Raemont wrote.
• The service promises to assess blood markers “in the context of lifestyle factors and longevity,” with ranges created from “cutting-edge research,” according to Ultrahuman.